ANHL1522: Durable Immunity to EBV post Rituximab and Third Party LMP-specific T-cells: A Children’s Oncology Group Study
Wistinghausen B, et al.
Blood Advances
January 2024
Authors and Affiliates
Birte Wistinghausen 1, Keri Toner 2, Donald A Barkauskas 3, Lauren P Jerkins 4, Hannah Kinoshita 5, Pamela Chansky 6, Gloria Pezzella 7, Lauren Saguilig 4, Robert J Hayashi 8, Harshal A Abhyankar 9, Brooks Scull 10, Vivekanudeep Karri 10, Jay Tanna 5, Patrick J Hanley 1, Michelle L Hermiston 11, Carl E Allen 10, Catherine M Bollard 4;
1 Children's National Medical Center, Washington, District of Columbia, United States.
2 Children's National Health System, Washington, District of Columbia, United States.
3 University of Southern California, United States.
4 Children's National Hospital, United States.
5 Childrens National Medical Center, Washington, District of Columbia, United States.
6 The George Washington University School of Medicine and Health Sciences, United States.
7 Children's National Hospital, Washington, District of Columbia, United States.
8 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
9 Baylor College Of Medicine, Houston, Texas, United States.
10 Baylor College of Medicine, Houston, Texas, United States.
11 University of California, San Francisco, San Francisco, California, United States.